Therapeutic additions and possible deletions in oncology in 2011

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 1, 2012, Pages 15-17

  Holstein, S A ^a   Hohl, R J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CRIZOTINIB; DACARBAZINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; IPILIMUMAB; PACLITAXEL; PEPTIDE VACCINE; PLACEBO; PREDNISONE; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; VEMURAFENIB; XALKORI;

BREAST CANCER; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COLITIS; DIARRHEA; DRUG APPROVAL; DRUG INDICATION; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; GENE FUSION; HEALTH CARE COST; HODGKIN DISEASE; HUMAN; HYPERTENSIVE CRISIS; INOPERABLE CANCER; KERATOACANTHOMA; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; METASTATIC MELANOMA; ONCOGENE; OVERALL SURVIVAL; PANCREAS ISLET CELL TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; THYROID MEDULLARY CARCINOMA; TORSADE DES POINTES; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84055183554     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.288     Document Type: Review

References (15)

1. Hodi, F.S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
2. Chapman, P.B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
3. Ribas, A. et al. BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutationpositive metastatic melanoma (abstract 8509). J. Clin. Oncol. 29 (2011).
4. Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501-513 (2011).
5. Yao, J.C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514-523 (2011).
6. Wells, S.A. et al. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA) (abstract 5503). J. Clin. Oncol. 28, 421s (2010).
7. Choi, Y.L. et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734-1739 (2010).
8. Bryce, A. & Ryan, C.J. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor. Clin. Pharmacol. Ther. 91, 101-108 (2012).
9. de Bono, J.S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
10. Chen, R.W. et al. Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) (abstract 8031). J. Clin. Oncol. 29 (2011).
11. Pro, B. et al. Durable remissions with brentuximab vedotin (SGN-35): updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) (abstract 8032). J. Clin. Oncol. 29 (2011).
12. Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007).
13. Miles, D.W. et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28, 3239-3247 (2010).
14. Robert, N.J. et al. RIBBON-1: randomized, doubleblind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol. 29, 1252-1260 (2011).
15. Johnson, J.R. et al. Accelerated approval of oncology products: the Food and Drug Administration experience. J. Natl. Cancer Inst. 103, 636-644 (2011).